Mechanistically, the study identified modulation of the PI3K/AKT signaling pathway, a key driver of GBM, supporting the notion that these synthetic endocannabinoid analog may exert their anti‐cancer effects through receptor‐mediated and downstream metabolic mechanisms. The gene discussed is PIK3CA; the disease is cancer.